Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Molecular Basis of Angiogenesis and its Application
Keio J Med. 2024;73(1):12. doi: 10.2302/kjm.ABSTRACT_73_1-1.ABSTRACTAngiogenesis, the development of new blood vessels, is a fundamental physiological process. In addition, angiogenesis plays a key role in the pathogenesis of several disorders, including cancer and eye disorders such as diabetic retinopathy and age-related macular degeneration (AMD). However, identifying the regulators of angiogenesis proved challenging. Numerous factors that stimulated angiogenesis in various bioassays were identified, but their pathophysiological role remained unclear. In 1989, we reported the isolation and cloning of vascular endothelia...
Source: The Keio Journal of Medicine - March 24, 2024 Category: Universities & Medical Training Authors: Napoleone Ferrara Source Type: research
Comparing the efficacy of glucocorticoids and anti-VEGF in treating diabetic macular edema: systematic review and comprehensive analysis
This study included randomized controlled trials up to February 2023 comparing the efficacy of corticosteroid-related therapy and anti-VEGF therapy. PubMed, the Cochrane Library, and Embase were searched, and the quality of the studies was carefully assessed. Finally, 39 studies were included.ResultsResults at 3-month followup showed that intravitreal injection of bevacizumab (IVB) + triamcinolone acetonide (TA) was the most beneficial in improving best-corrected visual acuity and reducing the thickness of macular edema in the center of the retina in patients with DME. Results at 6-month follow-up showed that intravitreal ...
Source: Frontiers in Endocrinology - March 22, 2024 Category: Endocrinology Source Type: research
Cancers, Vol. 16, Pages 1249: Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations
Carles Escriu
Contrary to Pemetrexed-containing chemo-immunotherapy studies, Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel (ABCP) treatment has consistently shown clinical benefit in prospective studies in patients with lung cancer and actionable mutations, where intracranial metastases are common. Here, we aimed to describe the real-life population of patients fit to receive ABCP after targeted therapy and quantify its clinical effect in patients with brain metastases. Patients treated in Cheshire and Merseyside between 2019 and 2022 were identified. Data were collected retrospectively. A total of 34 patient...
Source: Cancers - March 22, 2024 Category: Cancer & Oncology Authors: Marcus Rathbone Conor O ’Hagan Helen Wong Adeel Khan Timothy Cook Sarah Rose Jonathan Heseltine Carles Escriu Tags: Article Source Type: research
A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy
In this study, we sought to identify clinical and molecular factors to predict overall survival in recurrent glioma patients receiving bevacizumab-containing regimens. A cohort of 102 patients was retrospectively collected from June 2011 to January 2022 at our institution. A nomogram was generated by Cox regression and feature selection algorithms based on 19 clinicopathological and 60 molecular variables. The model's performance was internally evaluated by bootstrapping in terms of discrimination and calibration. The median overall survival from the initiation of bevacizumab administration to death or last follow-up was 1...
Source: Hormones and Cancer - March 22, 2024 Category: Cancer & Oncology Source Type: research
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study
We present results of the prespecified interim futility analysis. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Atsuo Takashima, Pilar Garc ía-Alfonso, Raimundo Manneh, Ali Ayberk Beşen, Yong Sang Hong, Pieter-Jan Cuyle, Patricio Yanez, Matthew Burge, Takayuki Yoshino, Tae Won Kim, Karen Cui, Chenxiang Li, Rishi Jain, David Adelberg, Julien Taieb Tags: Original Research Source Type: research
Bevacizumab ‐induced pulmonary cystic disease
We report a unique case of a 73-year-old woman with a past medical history of metastatic endometrial adenocarcinoma status post-chemotherapy with bevacizumab that presented with worsening respiratory symptoms. A follow-up chest CT scan post chemotherapy showed the transformation of the metastatic lesions into cystic formations. After further extensive evaluation, she was diagnosed with pulmonary cystic disease secondary to bevacizumab. This case illustrates a rare presentation of secondary pulmonary cystic disease following Bevacizumab therapy in a patient with metastatic endometrial adenocarcinoma. It highlights the impor...
Source: Respirology Case Reports - March 20, 2024 Category: Respiratory Medicine Authors: Dakota McNierney,
Fahed Owda,
Hamza A. Salim,
Shatha M. A. Mallah,
Jehad Azar Tags: CASE REPORT Source Type: research
PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
CONCLUSION: Combined IBC treatment achieved superior DCR and PFS compared with IC or BC in patients with PD-L1-negative metastatic lung adenocarcinoma, while did not increase the adverse events.PMID:38499838 | DOI:10.1007/s00432-024-05637-1 (Source: Cancer Control)
Source: Cancer Control - March 19, 2024 Category: Cancer & Oncology Authors: Yihui Ge Yujing Zhan Jie He Juan Li Jian Wang Xiaojuan Wei Chunni Wang Aiqin Gao Yuping Sun Source Type: research
PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
CONCLUSION: Combined IBC treatment achieved superior DCR and PFS compared with IC or BC in patients with PD-L1-negative metastatic lung adenocarcinoma, while did not increase the adverse events.PMID:38499838 | DOI:10.1007/s00432-024-05637-1 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Yihui Ge Yujing Zhan Jie He Juan Li Jian Wang Xiaojuan Wei Chunni Wang Aiqin Gao Yuping Sun Source Type: research
